38 results about "Particulate antigen" patented technology

Methods for eliciting in an animal in need thereof a cell-mediated immune response specific to an antigen, the method comprising providing an antigen preparation comprising particles on the surface of which the antigen is attached, and administering the antigen preparation to the animal, wherein the particles are taken up by antigen presenting cells (APC) of the animal via phagocytosis, forming a phagosome inside the APC, wherein the antigen is attached to the surface of the particle in such a way that the antigen is released in the phagosome before the phagosome fuses with a late endosome or a lysosome, and wherein the antigen is cross-presented on a Class I MHC molecule. Also provided are particulate antigen preparations or particulate vaccines that can be delivered to an animal in need thereof for vaccination against, for preventing or treating, a disease related to the antigen, such as cancer and a viral infection.

This invention provides a first composition comprising a pharmaceutically acceptable particle and a stable HIV-1 pre-fusion envelope glycoprotein trimeric complex operably affixed thereto. This invention further provides a second composition comprising (a) a pharmaceutically acceptable particle, (b) an antigen, and (c) an agent which is operably affixed to the particle and is specifically bound to the antigen, whereby the antigen is operably bound to the particle. Finally, this invention provides related nucleic acids, vectors, cells, compositions, production methods, and prophylactic and therapeutic methods.

The invention discloses a humanized neutralizing antibody (RVFab8) against rabies virus glycoprotein, which is obtained through screening by utilizing phage display technology. The antibody specifically identifies the granule antigen of the rabies virus, is against the rabies virus glycoprotein G, has obvious immunofluorescence reaction and enzyme linked immunosorbent assay with the rabies virus and has the neutralizing activity function against rabies virus infection. The antibody can be prepared into the specific antibody drugs for preventing and treating rabies, thereby being clinically used for preventing and treating rabies caused by the rabies virus.

A one-step method for producing antigen loaded antigen-presenting cells from monocytes ex vivo has been found which comprises contacting the monocytes with a composition comprising an activator such as TNF alpha preferably in combination with at least one growth factor such as GM-CSF and at least one soluble or particulate antigen. According to the methods of the present invention, antigen-loaded dendritic cell vaccines can be generated within as little as three (3) days. In another method of the present invention, antigen loaded antigen-presenting cells are produced from monocytes ex vivo by contacting the monocytes with TNF alpha and granulocyte-macrophage colony stimulating factor at one time point to form antigen-presenting cells and then contacting antigen-presenting cells with soluble or particulate antigenic material antigen-presenting cells, wherein the antigen loaded antigen-presenting cells are produced in less than four days. The present invention also includes a vaccine which comprises monocyte-derived antigen loaded antigen-presenting cells, wherein the antigenpresenting cells are composed of two or more subsets selected from the group consisting of Langerhans cells with surface markers (CD 1 a+CD207+); interstitial dendritic cells with surface markers (CD 1a+CD207−); double negative dendritic cells with surface markers 20 (CD 1 a−CD 14−); and dendritic cells with surface markers (CD 14+CD 1 a−CD209+).

The invention provides a type-A foot-and-mouth disease virus-like particulate antigen. The particulate antigen is formed by assembling antigen proteins VP2, VP3 and VP1 of type-A foot-and-mouth disease virus epidemic strains, and the antigen proteins VP2, VP3 and VP1 are separately coded by nucleotide sequences of specific sequences. A vaccine prepared from the type-A foot-and-mouth disease virus-like particulate antigen has good immunogenicity aiming at the type-A foot-and-mouth disease virus epidemic strains. Vaccines prepared from the antigen and a type-O foot-and-mouth disease virus-like particulate antigen can respectively protect the type-A foot-and-mouth disease virus epidemic strains and type-O foot-and-mouth disease viruses.

The invention relates to a preparation method of O-type foot-and-mouth disease virus-like particles, which comprises the following steps: recombining a VP0 gene, a VP3 gene and a VP1 gene of an O-type foot-and-mouth disease virus to a pETSUMO vector, forming fusion protein genes with SUMO, amplifying the three fusion protein genes, cloning into the same pET28a expression vector to obtain a recombinant expression vector pET28a-SUMO-VP0-SUMO-VP3-SUMO-VP1, transforming the expression vector into escherichia coli to express fusion protein, and removing SUMO, VP0, VP3 and VP1 proteins from the expressed fusion protein by enzyme digestion under the condition of 10U/mL Ulp1 protease concentration to form the O-type foot-and-mouth disease virus-like particles through self-assembly. The method can be used to efficiently prepares the O-type foot-and-mouth disease virus-like particles, and is suitable for large-scale industrial production.

The invention relates to an avian influenza virus-like particle vaccine, the avian influenza virus-like particle vaccine comprises an immune dose of H5 subtype and/or H7 subtype avian influenza virus-like particle antigen and a pharmaceutically acceptable carrier, and the avian influenza virus-like particle antigen is formed by assembling HA, NA and M1 antigen proteins of H5 subtype and/or H7 subtype avian influenza viruses. The avian influenza virus-like particle vaccine disclosed by the invention has good immunogenicity, and the immune effect is better than that of a commercial inactivated vaccine with higher antigen content when the dosage is low.

The invention discloses a solution for large-scale production of foot-and-mouth disease virus-like particle antigens and a purification and assembly method, belonging to the technical field of biological medicines. With the method, foot-and-mouth disease virus-like particles with high purity and high assembly rate is purified and prepared from foot-and-mouth disease virus recombinant protein fermentation liquor expressed by escherichia coli. The method is simple in technological process, convenient to operate and high in production efficiency; the purification yield of the foot-and-mouth disease virus-like particles reaches 90% or above, and the in-vitro assembly rate of the particles reaches 67%; and the method is particularly suitable for industrial production of foot-and-mouth disease virus-like particle antigens expressed by escherichia coli.

According to the invention, a recombinant baculovirus capable of being efficiently replicated is obtained by modifying a GP5-M protein, the culture titer of the recombinant baculovirus is relatively high, the prepared virus-like particles similar to PRRSV virions are further compounded with IgM to prepare an IgM-RPPSV VLPs immune complex, and the IgM-RPPSV VLPs immune complex can stimulate an organism to generate a high-concentration antibody earlier.

The invention provides an O-type foot and mouth disease virus-like particle antigen. The O-type foot and mouth disease virus-like particle antigen is a CATHAY-type O-type foot and mouth disease virus-like particle antigen and the CATHAY-type O-type foot and mouth disease virus-like particle antigen is composed from the composition of CATHAY-type O-type foot and mouth disease virus VP0, VP3 and VP1antigen proteins. The O-type foot and mouth disease virus-like particle antigen has good immunogenicity, a prepared vaccine can realize primary immunization, complete protection against O-type foot and mouth disease virus can be realized on the 14th day after immunization, the titer of a generated antibody is higher than the titer of a commercial inactivated vaccine, and the protective immune period can last for at least 133 days. The invention further relates to a prepared vaccine composition and a preparation method thereof and application.

The invention relates to a vaccine composition for resisting H7 subtype avian influenza virus, the vaccine composition comprises an immune dose of H7 subtype avian influenza virus-like particle antigen and a pharmaceutically acceptable carrier, and the H7 subtype avian influenza virus-like particle antigen is assembled by H7 subtype avian influenza virus HA, NA and M1 antigen proteins. The vaccine composition for resisting the H7 subtype avian influenza virus can achieve the immune effect of an inactivated vaccine with a higher immune dose when the immune dose is low, the high-titer antibody is generated in a shorter time, the poultry are protected, the vaccine composition is good in stability, and the stability and durability of immunogenicity of the vaccine composition are advantageously guaranteed.

The invention discloses an avian influenza virus-like particle antigen, a vaccine, a preparation method of the avian influenza virus-like particle antigen and application of the avian influenza virus-like particle antigen or the vaccine. A strain of recombinant baculovirus based on tandem expression of HA, NA and M1 genes of an H7N9 subtype avian influenza virus transfects insect cells and performs self-assembly to form the avian influenza virus-like particle antigen; and the virus-like particle antigen prepared according to the invention is used for preparing the vaccine. After a chicken group is immunized by the vaccine prepared according to the invention, HI antibodies, neutralizing antibodies and IgY antibodies with the higher titer can be generated, 100-percent clinical protection onthe H7N9 subtype highly pathogenic avian influenza virus can be provided, and virus expelling can be effectively inhibited. The rely on the chicken embryos is avoided; the production cost is low; theperiod is short; and higher protection capability can be induced only by once low-dose immunization. A foundation is laid for industrial production of VLP vaccines.

The invention belongs to the technical field of biology and particularly relates to an H7N9 subtype avian influenza virus-like particle vaccine preparation as well as preparation and application thereof. The H7N9 subtype avian influenza virus-like particle vaccine preparation provided by the invention comprises a recombinant chimeric protein HMN and H7N9 subtype avian influenza virus-like particles, wherein the recombinant chimeric protein HMN is formed by chimeric combination of avian influenza virus conservative epitopes, bee venom signal peptides and 6x-His tag proteins. The recombinant chimeric protein HMN is combined with an H7N9 subtype avian influenza virus-like particle antigen, so that the defect that an avian influenza virus-like particle vaccine is insufficient in cross protection effect on variant strains is overcome, complete protection is provided for attack of the H7N9 subtype variant strains, and thus, the avian influenza epidemic situation is more effectively prevented and controlled.

The invention discloses a cat parvovirus-like particle and a preparation method and application thereof.A VP2 sequence of an autonomously separated FPV JL-125 strain is selected for preparing a recombinant baculovirus FPV-VP2 strain, the FPV JL-125 strain and a current Chinese prevalent strain have high homology, after the VP2 sequence is optimized according to insect cell codons, the VP2 sequence is converted into a recombinant baculovirus FPV-VP2 strain, and the recombinant baculovirus FPV-VP2 strain is converted into a recombinant baculovirus FPV-VP2 strain. The prepared recombinant baculovirus FPV-VP2 strain can be used for correctly expressing the FPVVP2 protein. According to the invention, a full suspension culture process is adopted for culture, the expression quantity is greatly improved, and the HA titer can reach 220-221, which is 256-512 times of the culture titer of wild viruses. The expressed protein can be autonomously assembled into complete FPV virus-like particles, the space structure of the protein is similar to that of an original virus, and the virus-like particles are high in titer and higher in safety and have the advantages of stimulating humoral immunity and cellular immunity at the same time. According to the invention, the virus-like particle antigen is prepared by using a genetic engineering means, the novel cat parvovirus-like particle vaccine is prepared, and the vaccine has higher safety and effectiveness.

The preparation method comprises the following steps: firstly, designing a broad-spectrum rabies virus-like particle antigen by using RVLPs, which is self-assembled by glycoprotein RVGP and matrix protein RVMP of a CVS strain rabies virus RABV, as an antigen; then, the RVGP, the RVMP and the EGFP are jointly constructed into a eukaryotic expression vector pcDNA3.1 (+), and the eukaryotic expression vector is named as pcDNA3.1 (+)-RVLPs-EGFP. Each protein has an independent promoter (CMV), a ribosome binding site (Kozak sequence) and a PloyA tail (PA) so as to ensure the surface level of each protein, and meanwhile, EGFP (enhanced green fluorescent protein) is used for monitoring the expression of the target protein in real time so as to construct a eukaryotic recombinant expression plasmid; and then transfecting HEK-293 cells with the eukaryotic recombinant expression plasmids, carrying out amplification and passage on the cells, screening and identifying, and screening to obtain the positive monoclonal cell strain HEK-293/RVLPs capable of stably and efficiently expressing RVLPs. The obtained antigen has post-translational modification of mammalian cells, the defect that RVLPs derived from bacteria, yeast, insects and plant cells show low immunogenicity due to incorrect glycosylation modification is overcome, and a foundation is laid for large-scale production of the RVLPs antigen.